Positive results for LPCN 1021 for Low Testosterone treatment - Lipocine Inc.

Lipocine Inc.announced positive top-line efficacy results from its ongoing Study of Oral Androgen Replacement ("SOAR") pivotal Phase III clinical study evaluating efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with Low Testosterone ("Low T"). Overall, the study demonstrated positive results with respect to the trial's primary efficacy endpoint with no serious adverse events. Lipocine continues to expect to file a New Drug Application ("NDA") with the FDA in the second half of 2015.